Katsumasa Nakajima

age ~50

from Winchester, MA

Katsumasa Nakajima Phones & Addresses

  • 19 Nassau Dr, Winchester, MA 01890 • 7813691930
  • 306 Forest St, Arlington, MA 02474 • 7813161697
  • Cambridge, MA
  • Everett, MA
  • Bear, DE
  • Newark, DE

Work

  • Position:
    Clerical/White Collar

Education

  • Degree:
    Graduate or professional degree

Us Patents

  • Organic Compounds

    view source
  • US Patent:
    8084448, Dec 27, 2011
  • Filed:
    Mar 29, 2007
  • Appl. No.:
    12/295545
  • Inventors:
    Alan Neubert - North Attleborough MA,
    David Barnes - Waban MA,
    Young-Shin Kwak - Lexington MA,
    Katsumasa Nakajima - Winchester MA,
    Gregory Raymond Bebernitz - Stow MA,
    Gary Mark Coppola - Budd Lake NJ,
    Louise Kirman - Swampscott MA,
    Michael H. Serrano-Wu - Belmont MA,
    Travis Stams - Stow MA,
    Sidney Wolf Topiol - Fair Lawn NJ,
    Thalaththani Ralalage Vedananda - Shrewsbury MA,
    James Richard Wareing - Stow MA,
  • Assignee:
    Novartis AG - Basel
  • International Classification:
    A61K 31/55
    A61K 31/445
    A61K 31/41
    C07D 487/00
    C07D 401/00
    C07D 285/10
  • US Classification:
    51421207, 514326, 514362, 540523, 546209, 548135
  • Abstract:
    Compounds of the formula.
  • Organic Compounds

    view source
  • US Patent:
    20080262050, Oct 23, 2008
  • Filed:
    Dec 6, 2006
  • Appl. No.:
    12/096439
  • Inventors:
    David Barnes - Waban MA,
    Gregory Raymond Bebernitz - Stow MA,
    Gary Mark Coppola - Budd Lake NJ,
    Katsumasa Nakajima - Winchester MA,
    Travis Stams - Stow MA,
    Sidney Wolf Topiol - Fair Lawn NJ,
    Thalaththani Ralalage Vedananda - Shrewsbury MA,
    James Richard Wareing - Stow MA,
  • International Classification:
    A61K 31/433
    C07D 285/10
    A61P 3/00
    A61P 25/00
    A61P 9/00
    C07D 417/02
  • US Classification:
    514362, 548135
  • Abstract:
    Compounds of the formulaare inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. The compounds of formula (I) may be employed for prevention and/or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels, conditions that accompany type-2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat and/or prevent cancer, osteoporosis, neurodegenerative and infectious diseases, and diseases involving inflammation and the immune system.
  • 1,1,3-Trioxo-1,2,5-Thiadiazolidines And Their Use As Ptp-Ases Inhibitors

    view source
  • US Patent:
    20080293782, Nov 27, 2008
  • Filed:
    Dec 6, 2006
  • Appl. No.:
    12/096421
  • Inventors:
    David Barnes - Waban MA,
    Gary Mark Coppola - Budd Lake NJ,
    Robert Edson Damon - Hopkinton MA,
    Katsumasa Nakajima - Winchester MA,
    Brian Christopher Raudenbush - Beacon Falls CT,
    Travis Stams - Stow MA,
    Sidney Wolf Topiol - Fair Lawn NJ,
    Thalaththani Ralalage Vedananda - Shrewsbury MA,
  • International Classification:
    A61K 31/433
    C07D 285/10
    A61P 3/10
    A61P 3/04
    A61P 9/10
    A61P 25/28
    A61P 35/00
  • US Classification:
    514362, 548135
  • Abstract:
    Compounds of the formulaare inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of formula (I) may be employed for prevention and/or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels, conditions that accompany type-2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat and/or prevent cancer, osteoporosis, neurodegenerative and infectious diseases, and diseases involving inflammation and the immune system.
  • Organic Compounds

    view source
  • US Patent:
    20100022513, Jan 28, 2010
  • Filed:
    Jul 14, 2009
  • Appl. No.:
    12/502669
  • Inventors:
    Cornelia Jutta Forster - Cambridge MA,
    Young-Shin Kwak - Cambridge MA,
    Katsumasa Nakajima - Cambridge MA,
    Bing Wang - Cambridge MA,
  • International Classification:
    A61K 31/553
    C07D 249/14
    C07D 281/06
    C07D 413/12
    A61K 31/4196
    A61K 31/5377
    A61P 3/10
    A61P 3/04
  • US Classification:
    51421115, 5482654, 540544, 544132, 514383, 5142362
  • Abstract:
    The invention relates to compounds of formula (I):where A is an optionally substituted heteroaryl, useful for treating disorders mediated by acyl coA-diacylglycerol acyl transferase 1 (DGAT1), e.g. metabolic disorders. The invention also provides methods of treating such disorders, and compounds and compositions etc. for their treatment.

Get Report for Katsumasa Nakajima from Winchester, MA, age ~50
Control profile